drugset / Trial / NCT05504837
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Timeline
- Start
- 2023-06-30
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KB407 | Unknown | — | Inhaled |